ROTH MKM initiated coverage on Inventiva with a new price target
$IVA
Biotechnology: Pharmaceutical Preparations
Health Care
ROTH MKM initiated coverage of Inventiva with a rating of Buy and set a new price target of $11.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/6/2025 | $13.00 | Outperform | Wolfe Research |
| 9/3/2025 | $20.00 | Buy | H.C. Wainwright |
| 8/27/2025 | $26.00 | Overweight | Piper Sandler |
| 2/21/2025 | $10.00 | Buy | TD Cowen |
| 11/12/2024 | $3.00 | Neutral | UBS |
| 10/27/2023 | $12.00 | Buy | Canaccord Genuity |
| 5/31/2023 | $11.00 | Buy | ROTH MKM |
| 5/19/2023 | Sell → Buy | Societe Generale |
SCHEDULE 13D/A - Inventiva S.A. (0001756594) (Subject)
SCHEDULE 13D/A - Inventiva S.A. (0001756594) (Subject)
6-K - Inventiva S.A. (0001756594) (Filer)
Cash and cash equivalents at €97.6 million, and €24.7 million in short-term deposits2 as of September 30, 2025.Revenues of €4.5 million for the first nine months of 2025.Cash runway expected until the end of the first quarter of 20273, including net proceeds from the November 2025 public offering. Daix (France), New York City, (New York, United States), November 21, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis ("MASH"), today reported its cash position as of September 30, 2025 and its revenues for t
Daix (France), New York City (New York, United States), November 17, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis ("MASH"), today announced that the underwriters of the previously announced public offering in the United States (the "Offering") of 38,961,038 American Depositary Shares ("ADSs"), each representing one ordinary share of the Company with a nominal value of €0.01, have exercised in full their option (the "Underwriters' Option") to purchase 5,844,155 additional ADSs (the "Additional ADSs").
Daix (France), New York City (New York, United States), November 13, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis ("MASH"), announced the trading resumption of its ordinary shares on the regulated market of Euronext in Paris as from 4:30 p.m. (CET). Trading of the ordinary shares of the Company was halted, at the Company's request, on November 13, 2025, from 9:00 a.m. (CET), in the context of the previously announced public offering by the Company in the United States only of new American Deposita
Wolfe Research initiated coverage of Inventiva with a rating of Outperform and set a new price target of $13.00
H.C. Wainwright resumed coverage of Inventiva with a rating of Buy and set a new price target of $20.00
Piper Sandler initiated coverage of Inventiva with a rating of Overweight and set a new price target of $26.00
Daix (France), New York City (New York, United States), October 1, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis ("MASH"), today announced the appointment of Andrew Obenshain as Chief Executive Officer ("CEO") of the Company. Mr. Obenshain will also join the Company's Board of Directors. He succeeds Frédéric Cren, the Company's co-founder, who has served as CEO since its inception in 2012. Mr. Cren is also stepping down from the Board of Directors and will work with Mr. Obenshain to ensure a smooth tr
Jason Campagna, MD, PhD, joins Inventiva as President of R&D and Chief Medical Officer, succeeding Pierre Broqua, PhD, and Michael Cooreman, MDMartine Zimmermann, PharmD, joins as Executive Vice President of Regulatory Affairs and Quality AssuranceThese key leadership appointments underscore Inventiva's commitment to long-term growth and operational excellence, with topline results from NATiV3 on track for the second half of 2026 Daix (France), New York City (New York, United States), July 9, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic
Daix (France), New York City (New York, United States), June 10, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis ("MASH"), today announced the appointment of Renée Aguiar-Lucander to its Board of Directors. The appointment was approved by shareholders at the recent Company's Annual General Meeting. Mark Pruzanski, Chairman of Inventiva: "We are thrilled to welcome Renée to the Board at this pivotal moment in Inventiva's journey. Her exceptional track record in our industry speaks for itself and will be
Financing follows completion of enrollment of Phase 3 NATiV3 study evaluating lanifibranor in MASH and satisfaction of other specified conditions. Daix (France), New York City (New York, United States), May 5, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis ("MASH") and other diseases with significant unmet medical needs, today announced that the Board of Directors called the second tranche of its previously announced1 structured financing of up to €348 million (the "Structured Financi
Revenues of €9.2 million for the full year of 2024Cash and cash equivalents at €96.6 million as of December 31, 2024 First tranche of up to €348 million Structured Financing closed with aggregate gross proceeds of €116 millionLast patient screened in the NATiV3 Phase 3 clinical trial of lanifibranor in MASH early in January 2025 Pipeline prioritization plan presented to the workers council to focus exclusively on the development of lanifibranor, stopping all preclinical research activities and reducing the workforce by 50% Daix (France), New York City (New York, United States), March 26, 2025 – Inventiva (Euronext Paris and NASDAQ:IVA) (the "Company"), a clinical-stage biopharmaceutical c
Daix (France), New York City (New York, United States), March 19, 2025 – Inventiva (Euronext Paris and NASDAQ:IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis ("MASH") and other diseases with significant unmet medical needs, today announced that its management team will host a webcast to present the Company's 2024 full-year financial results on Thursday, March 27, 2025. Inventiva's 2024 full-year financial results will be published on Wednesday, March 26, 2025 at 4:00 pm (New York), 9:00 pm (Paris). Frédéric Cren, CEO and cofounder
SC 13D/A - Inventiva S.A. (0001756594) (Subject)
SC 13D/A - Inventiva S.A. (0001756594) (Subject)
SC 13D/A - Inventiva S.A. (0001756594) (Subject)